Asset profile
Rilparencel · Neo-Kidney Augment / REACT
Cell therapy
Evidence outlook · registrational
Chronic Kidney Disease: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2029-12.
NCT05018416: Although participants were randomized between two rilparencel dosing regimens, the study was open-label and included no placebo or other comparator arm. The primary eGFR progression and safety results are not available, so the trial cannot provide a controlled comparison of rilparencel’s effects.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
December 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.